|Hutchison China Meditech
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Hutchison China Meditech Share Discussion Threads
Showing 976 to 999 of 1000 messages
|Everything in place and our fantastically talented CSO Dr Su now on the Board, excellent..........
We have a fantastic Board with a great mix of commercial and scientific talent
The Company is in great shape for the big push forward to become a large Biopharma over the next few years
Brilliant long term investment opportunity|
|All these to come soon (well, during FY17) and many are very material
Target to publish data on 4 drug candidates in 5 Phase II-III studies:
1. Phase II median overall survival data in PRCC patients;
2. Phase IIb data in second-line NSCLC combinations with Tagrisso® & Iressa®;
3. Phase II dose finding data in ccRCC combination with durvalumab (PD-L1).
4. Phase III FRESCO study full data set publication in CRC patients.
5. Preliminary Phase II proof-of-concept data in medullary and differentiated thyroid cancer patients.
6. Preliminary Phase Ib proof-of-concept data in hematological cancer patients.
Target to achieve multiple late-stage/global clinical & regulatory milestones by end of 2017:
1. Initiate global Phase III study in PRCC patients;
2. Initiate global Phase III study in second-line NSCLC in combination with Tagrisso®;
3. Submit New Drug Application (“NDA”) in China in third-line CRC;
4. Initiate China Phase III study in second-line gastric cancer patients;
5. Complete enrollment of Phase III FALUCA study in third-line NSCLC;
6. Initiate U.S. Phase I bridging study in Caucasian patients.
7. Initiate China Phase III study in first-line EGFR-mutant NSCLC patients with brain metastasis;
8. Initiate China Phase II study in glioblastoma (primary brain cancer).
9. Initiate U.S. Phase II study in NET patients.
Initiate Australian Phase Ib/II expansion study in hematological cancer patients.
11. Initiate Phase I studies in China in hematological cancer patients.
12. Initiate Phase I studies in Australia/China in solid tumor patients.|
|New York closes at £31 equivalent,London decides to push the price down on limited volume,offering stock at a £29-75,4% lower.Time will tell who wins the day.|
|Yes, co-ordinate buying by the Board including the new Non Execs - they know what the company will be worth in a few years time for sure.........
I look forward to meeting the new Non Execs at the AGM on the 27th April|
|BOD. buying en masse, tasty. Just what we need on a Monday am.|
|Yes,market makers will deal in either quote.The other day,when they were bidding well below the closing price in New York,it's more than likely that they had gone short on the Nasdaq with the intention of trying to square their position by potentially buying back cheap stock in London.They will arbitrage the position quite happily especially when they benefit from a wide spread.You have to check both markets and bear in mind that brokers will be trading away on both sides of the Atlantic.|
Also I notice that when you buy ADR's your Broker may end up sourcing AIM shares and when you buy AIM shares the Broker may end up sourcing ADR's in the background.
In other words there is a way in which both exchanges can interchange or internally trade the two types of securities. There is some information on HCM's website about it.|
|The arrival of sustained US interest will dictate the price here.Recently,the value of dealings on the NASDAQ market has been near double the value of trades on the London market.The London market likes to use a wide spread to manoeuvre during the hours when it is the only exchange making a quote but has to fall into line when New York opens.Back in the 1980s,London dealings in Glaxo became subordinated to those in ADRs in New York and,writ small,this will happen here.Presentations in the US is all part and parcel of wooing US investors and any future financing is likely to be concentrated there.Currency considerations are also paramount.The ADS's offer a dollar exposure,preferable to purchasing a sterling denominated AIM listed stock .I don't know whether a UK domiciled broker like Panmure is going to be that influential going forward.The US will determine whether the stock is to be considered cheap or dear and the weight of money looking to buy will be key.|
|I think the current valuation is right, I never understood the lack of enthusiasm by U.S. Institutional Investors until but big volumes since the FY16 results
The Company has done a brilliant job in quantifying the types of numbers we will see from drug candidates
This is another Genmab IMO
$10bn mcap by 2020, $15bn by 2025 IMO
And we have some very material developments that could occur shortly as our CEO said on the video last week - something is brewing|
|I presume the market saw a bit of selling late morning,early afternoon.Topped up prior to US opening without difficulty.|
|May the shortage continue.............
What have you seen later in the day steeple, if I may ask?|
|They're short of stock.On quote and deal,they'll bid for size but only offer 100 shares outright.|
|They're not taking any chances,have immediately closed any arbitrage potential.|
|Amazing how some analysts reading the F20 can translate into this
The big difference now is the Company is talking about future sales numbers and quantifying some of the value in the IP. it's always been there in the Edison reports but now we have the Company themselves giving forward guidance.
This is the advantage of the NASDAQ listing. American investors expect forward guidance. The fact we beat guidance for FY16 helped|
|Yes,£33-60 bid equivalent at NASDAQ CLOSE .
Makes you wonder why the light that burnt so pale can suddenly burn so brightly.|
|At 7.45pm UK time the price was $20.53 up $4.43 i.e. 28.3%.
x2 = $41.06 ...... £ equivalent = £33.82
And still rising!!!|
|Currently $18 bid US is equivalent £29-50 UK.|
|indeed, I agree, what I meant was they could buy back the rights to the candidate in question so they own the asset in ROW. They would of course need to partner to market it.|
|Not a good idea for HCM to buy ROW rights - how would they market it ? Partnering is the key to their strategy and makes up for the fact that they are China based and takeover proof.
|From yesterdays call transcript:-
"And when you add it all up, you have a situation where the clinical spend is more than the profits coming out of China. So, you have a loss for the full year. But we have probably two or three, potentially four, things that we are working on that could significantly alter this picture."
The last sentence is particularly interesting|
|Panmure Gordon 2900p targetDr Mike Mitchell, an analyst at broker Panmure Gordon, thinks they can go further: "We believe the business has started to demonstrate the quality of its strategy and ability to execute in one of the most challenging areas of medicine with some potentially transformational programmes, covering 8 drug candidates now in 30 active clinical trials. "With today's announcement, we consider our investment thesis for Hutchison China MediTech not only affirmed but also reinforced," he says. Still rating Chi-Med shares a 'buy', Mitchell ramps up his price target by 9% from 2,656p to 2,900p, which, if reached, would be a record high.US has woken up with sizeable volume on NASDAQ.This stock is well held with a blue chip list of holders,Schroders,Prudential,Baillie Gifford and Mark Slater's fund has a short 6% .Matthew International have been adding .Oh and the Investors Chronicle recommended buy at the end of last week.Finally things are bubbling.|
|Quite a few presentations in the US over the next few weeks. Lets hope they finally wake up.
Davey, are you happy with those peak CRC revenue figures?|
|This will be a $10bn mcap company within the next 5-10 years IMO
Their biggest strength is the consistency of their growth and execution
They have a clear strategy, do not deviate from it, and always deliver what they promise.|